JP2022513076A5 - - Google Patents

Info

Publication number
JP2022513076A5
JP2022513076A5 JP2021527119A JP2021527119A JP2022513076A5 JP 2022513076 A5 JP2022513076 A5 JP 2022513076A5 JP 2021527119 A JP2021527119 A JP 2021527119A JP 2021527119 A JP2021527119 A JP 2021527119A JP 2022513076 A5 JP2022513076 A5 JP 2022513076A5
Authority
JP
Japan
Prior art keywords
vector
immune cells
vector according
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021527119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513076A (ja
JP7630832B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062014 external-priority patent/WO2020106621A1/en
Publication of JP2022513076A publication Critical patent/JP2022513076A/ja
Publication of JP2022513076A5 publication Critical patent/JP2022513076A5/ja
Application granted granted Critical
Publication of JP7630832B2 publication Critical patent/JP7630832B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021527119A 2018-11-19 2019-11-18 Carおよびtcr形質導入用のモジュール式ポリシストロニックベクター Active JP7630832B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862769414P 2018-11-19 2018-11-19
US62/769,414 2018-11-19
US201862773394P 2018-11-30 2018-11-30
US62/773,394 2018-11-30
US201962791491P 2019-01-11 2019-01-11
US62/791,491 2019-01-11
PCT/US2019/062014 WO2020106621A1 (en) 2018-11-19 2019-11-18 A modular, polycistronic vector for car and tcr transduction

Publications (3)

Publication Number Publication Date
JP2022513076A JP2022513076A (ja) 2022-02-07
JP2022513076A5 true JP2022513076A5 (cg-RX-API-DMAC7.html) 2022-11-21
JP7630832B2 JP7630832B2 (ja) 2025-02-18

Family

ID=68982428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527119A Active JP7630832B2 (ja) 2018-11-19 2019-11-18 Carおよびtcr形質導入用のモジュール式ポリシストロニックベクター

Country Status (6)

Country Link
US (1) US20220033848A1 (cg-RX-API-DMAC7.html)
EP (1) EP3883955A1 (cg-RX-API-DMAC7.html)
JP (1) JP7630832B2 (cg-RX-API-DMAC7.html)
CN (1) CN113286813A (cg-RX-API-DMAC7.html)
TW (1) TW202033542A (cg-RX-API-DMAC7.html)
WO (1) WO2020106621A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773789B2 (ja) 2020-03-28 2025-11-20 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 癌の治療のための細胞免疫療法
GB202013477D0 (en) * 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
EP4267604A1 (en) * 2020-12-23 2023-11-01 Gadeta B.V. Chimeric, transmembrane proteins with bidirectional signalling activity
JP2024507929A (ja) * 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
IL310099A (en) * 2021-07-16 2024-03-01 Sana Biotechnology Inc Polycistronic vectors for cell-based therapies
AU2023275671A1 (en) * 2022-05-27 2024-11-14 Kite Pharma, Inc. Non-viral delivery of cell therapy constructs

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えctla4ポリペプチドおよびその製造方法
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
DK2348119T3 (en) * 2002-02-01 2017-08-21 Oxford Biomedica (Uk) Ltd Polycistronic lentiviral vector
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
EP1765846A4 (en) 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3053932B1 (en) 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CA2935951A1 (en) * 2014-01-08 2015-07-16 1Globe Biomedical Co., Ltd. Novel synthetic biology-based adcc technology
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
CN106456670B (zh) * 2014-04-25 2020-01-07 蓝鸟生物公司 制备过继性细胞疗法的改善方法
RS63601B1 (sr) * 2014-10-09 2022-10-31 Univ Yamaguchi Vektor ekspresije car i t ćelije koje eksprimiraju car
US10046047B2 (en) * 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
PL3280729T3 (pl) * 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
WO2016168595A1 (en) * 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
CN107849102B (zh) * 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
WO2016197108A1 (en) * 2015-06-05 2016-12-08 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
MX2018004721A (es) * 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
BR112018014585A2 (pt) * 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
CN106279438B (zh) * 2016-08-24 2019-10-22 北京领柯生物科技有限公司 新型嵌合抗原受体及其用途
BR112019019941B1 (pt) * 2017-03-27 2023-12-05 Noile-Immune Biotech, Inc Polinucleotídeo compreendendo uma sequência de base que codifica o receptor de antígeno quimérico, vetor e método
EP3625346A1 (en) * 2017-05-16 2020-03-25 Cairn Biosciences, Inc. Multiplex assay
TW201908335A (zh) * 2017-07-25 2019-03-01 美國德州系統大學評議委員會 增強之嵌合抗原受體及其用途
US20210106667A1 (en) * 2018-05-03 2021-04-15 Duke University Vaccine compositions and methods for enhanced antigen-specific vaccination
EP3743513A4 (en) * 2018-11-06 2021-11-24 Nantkwest, Inc. NK-92 CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR

Similar Documents

Publication Publication Date Title
Li et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
JP2022513652A5 (cg-RX-API-DMAC7.html)
Schmidt-Wolf et al. Activated T cells and cytokine-induced CD3+ CD56+ killer cells
CN111051502B (zh) 通用型嵌合抗原受体t细胞制备技术
US20180079824A1 (en) HER2/ErbB2 Chimeric Antigen Receptor
CN114144430A (zh) Cd7-car-t细胞及其制备和应用
AU679120B2 (en) Genetically modified human hematopoietic stem cells and their progeny
WO2019138217A1 (en) Method for transducing cells with a viral vector for the expression of a chimeric antigen receptor (car) or transgenic t-cell receptor (tcr)
EA035484B1 (ru) Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований
RU2016143385A (ru) Продукты определенного состава, содержащие генетически модифицированные т-клетки
JP7680032B2 (ja) A2/ny-eso-1特異的t細胞受容体およびその使用
Daenthanasanmak et al. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV
CN113330038A (zh) Cd20组合靶向的工程化免疫细胞
JP2023538463A (ja) がん及び自己免疫疾患及び炎症性疾患を治療する方法
US20220056411A1 (en) Methods for isolating cd8+ selected t cells
Muthuvel et al. Engineering safe anti-CD19-CD28ζ CAR T cells with CD8a hinge domain in serum-free media for adoptive immunotherapy
Hori et al. Human fetal liver-derived CD7+ CD2lowCD3-CD56-clones that express CD3 gamma, delta, and epsilon and proliferate in response to interleukin-2 (IL-2), IL-3, IL-4, or IL-7: implications for the relationship between T and natural killer cells
Yoshida et al. Induced immunity by expression of interleukin-2 or GM-CSF gene in murine neuroblastoma cells can generate antitumor response to established tumors
EP3750547A1 (en) Modified nk-92 cells, and therapeutic and diagnostic uses thereof
JP2023509512A5 (cg-RX-API-DMAC7.html)
Cooper Adoptive cellular immunotherapy for childhood malignancies
RU2786210C1 (ru) Биомедицинский клеточный продукт со специфической противоопухолевой активностью, представленный популяциями лимфокин-активированных киллеров и анти-HER2 CAR-γδΤ-ОИЛ и анти-HER2 CAR-T-NK
Ochi et al. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer
US20250345427A1 (en) Method
US20180363007A1 (en) A method for regenerating t cells and applications thereof